Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 6/20 | 0.45 |
| ▸ | AVPR1A | P37288 | 6/20 | 0.45 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 3/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8232872 | 0.91 | AVPR2 (0.47) | AVPR2AVPR1AMAPK1 | |
| SCHEMBL4507137 | 0.90 | AVPR2 (0.45) | AVPR2AVPR1AMAPK1MEN1KMT2A | |
| SCHEMBL4499296 | 0.89 | AVPR2 (0.55) | AVPR2AVPR1A | |
| SCHEMBL463144 | 0.84 | AVPR2 (0.55) | AVPR2AVPR1A | |
| SCHEMBL14460017 | 0.82 | AVPR2 (0.47) | AVPR2AVPR1AMEN1KMT2A | |
| SCHEMBL719285 | 0.82 | AVPR2 (0.53) | AVPR2AVPR1A | |
| SCHEMBL8232662 | 0.81 | AVPR2 (0.46) | AVPR2AVPR1AMAPK1 | |
| SCHEMBL8233185 | 0.81 | CNR1 (0.48) | AVPR2AVPR1AMAPK1GPR139CNR1 | |
| SCHEMBL417179 | 0.81 | AVPR2 (0.46) | AVPR2AVPR1AMAPK1KMT2ACNR1 | |
| SCHEMBL8233423 | 0.81 | GPR139 (0.53) | MEN1KMT2AGPR139 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005704-A1 | SUBSTITUTED ARYLIMIDAZOLONE AND TRIAZOLONE AS INHIBITORS OF VASOPRESSIN RECEPTORS | BAYER PHARMA AKTIENGESELLSHAFT (DE) | 2013-01-03 | — | — | US | disclosed |
| US-20130005704-A1 | SUBSTITUTED ARYLIMIDAZOLONE AND TRIAZOLONE AS INHIBITORS OF VASOPRESSIN RECEPTORS | BAYER PHARMA AKTIENGESELLSHAFT (DE) | 2013-01-03 | — | — | US | disclosed |
| EP-2027096-B1 | SUBSTITUTED ARYLIMIDAZ0L0NE AND TRIAZ0L0NE AS INHIBITORS OF VASOPRESSIN RECEPTORS | Bayer Pharma AG (DE) | 2012-05-23 | — | — | EP | disclosed |
| US-8084481-B2 | Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-27 | — | — | US | disclosed |
| US-8084481-B2 | Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-27 | — | — | US | disclosed |
| US-8084481-B2 | Substituted arylimidazolone and triazolone as inhibitors of vasopressin receptors | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-27 | — | — | US | disclosed |
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | BAYER HEALTHCARE AG (DE) | 2009-12-17 | — | — | US | disclosed |
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | BAYER HEALTHCARE AG (DE) | 2009-12-17 | — | — | US | disclosed |
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | BAYER HEALTHCARE AG (DE) | 2009-12-17 | — | — | US | disclosed |
| WO-2007134862-A1 | SUBSTITUTED ARYLIMIDAZ0L0NE AND TRIAZ0L0NE AS INHIBITORS OF VASOPRESSIN RECEPTORS | BAYER HEALTHCARE AG (DE) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312381-A1 | Substituted Arylimidazolone and Triazolone as Inhibitors of Vasopressin Receptors | AVPR2, AVPR1A, AVPR1B | AVPR2 1/4885AVPR1A 2/4885P2RX7 1263/4885 |
| US-20130005704-A1 | SUBSTITUTED ARYLIMIDAZOLONE AND TRIAZOLONE AS INHIBITORS OF VASOPRESSIN RECEPTORS | AVPR2, AVPR1A, AVPR1B | AVPR2 1/4885AVPR1A 2/4885P2RX7 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.